MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Wearing-off fluctuations"

  • 2023 International Congress

    Defining neuropsychiatric symptoms fluctuations in Parkinson’s disease

    A. Trinchillo, FP. Cucinotta, A. de Angelis, I. Cociasu, M. Horne, F. Morgante, L. Ricciardi (Giugliano in Campania, Italy)

    Objective: To evaluate the demographic and clinical correlates of Parkinson’s disease (PD) patients with fluctuations of neuropsychiatric symptoms (NPS-F). Background: Clinical correlates of fluctuations of…
  • 2023 International Congress

    Psychometric properties of the Neuropsychiatric Fluctuations Scale: preliminary results in patients with Parkinson’s disease

    C. Rodriguez-Blazquez, I. Debove, S. Murcia, A. Zenger, MM. Kurtis, E. Cubo, C. Falup-Pecurariu, KR. Chaudhuri, H. Reichmann, B. Falkenburger, S. Bostantjopoulou, P. Martinez-Martin, MJ. Forjaz, M. Bereau, P. Krack (Madrid, Spain)

    Objective: To assess the psychometric properties of the Neuropsychiatric Fluctuations Scale (NFS) [1] in patients with Parkinson’s disease (PD) Background: PD presents with non-motor symptoms…
  • 2023 International Congress

    Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort

    M. Fabbri, S. Tessier, V. Rousseau, JC. Corvol, A. Sommet, F. Tubach, Y. de Rycke, N. Bertille, Y. Selvarasa, S. Carvalho, C. Brefel-Courbon, F. Ory-Magne, O. Rascol (Blagnac, France)

    Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…
  • 2023 International Congress

    Retrospective exploration of the 5-2-1 criteria in clinical practice

    M. Karlstedt, A. Johansson (Stockholm, Sweden)

    Objective: To explore documentation in medical records (EMRs) of the 5 (5 oral levodopa doses taken/day) -2 (2hours of OFF time/day) -1 (1 hour of…
  • 2023 International Congress

    Sex differences for off episodes in Parkinson’s disease

    A. Ratnavel, C. Jiang, A. Liu, K. Wang, A. Tsai, K. Wyman-Chick, E. Bayram (La Jolla, USA)

    Objective: To determine the sex differences for the frequency, duration, and impact of off episodes in Parkinson’s disease (PD). Background: Dopamine replacement therapy through oral…
  • 2023 International Congress

    Continuous algorithmic insights into PD motor symptoms and individual treatment response

    M. Sander, FMJ. Pfister, G. Höglinger, J. Levin, A. Ceballos-Baumann, UM. Fietzek (Munich, Germany)

    Objective: To quantify the short-duration levodopa response using high resolution data derived from a wrist sensor and processed with advanced deep learning methods Background: The…
  • 2023 International Congress

    Safinamide in Parkinson´s Disease. A retrospective study

    M. Carmona-Abellan, M. Erburu, A. Cabrera, C. Garcia-Monco, K. Berganzo, B. Huete (Bilbao, Spain)

    Objective: To evaluate the safety of safinamide in Parkinson´s Disease (PD) and determine consequences of direct switch from rasagiline. Background: A wash-out period is recommended…
  • 2023 International Congress

    Analysis of a wearable sensor, STAT-on®, to detect motor complications in patients with Parkinson´s disease (PDp)

    J. Parra Serrano, MI. Morales Casado, N. Lopez Ariztegui (Toledo, Spain)

    Objective: Analysis of the use of a personalized monitoring device, STAT-on®, to detect motor complications in PDp and its impact on the therapeutic approach. Background:…
  • 2023 International Congress

    Response to Levodopa in Parkinson´s Disease Over Time. A 4-year Follow-up Study.

    D. Santos García, T. de Deus, C. Cores, M. Feal Painceiras, I. García-Díaz, M. íñiguez, J. Paz González, S. Jesús, M. Cosgaya, J. García Caldentey, N. Caballol, I. Legarda, J. Hernández Vara, I. Cabo, L. López Manzanares, I. González Aramburu, M. Avila, V. Gómez Mayordomo, V. Nogueira, J. Dotor, C. Borrué, B. Solano, M. álvarez Sauco, L. Vela, F. Escalante, E. Cubo, Z. Mendoza, J. Martínez Castrillo, P. Sánchez Alonso, M. Alonso Losada, N. López Ariztegui, M. Gastón, J. Kulisevsky, M. Seijo, C. Valero, R. Alonso Redondo, M. Buongiorno, C. Ordás, P. Martínez Martín, P. Mir, C. Coppadis (A Coruña, Spain)

    Objective: The aim of the present study was to analyze the response to levodopa in Parkinson´s disease (PD) patients with motor fluctuations followed up for…
  • 2023 International Congress

    Reliability of Indonesian Version Wearing Off Questionnaire

    R. Pinzon (Yogyakarta, Indonesia)

    Objective: This study measure the reliability of Indonesia version wearing off (WO) questionnaire for PD patients. Background: The wearing off phenomenon is disabling complication of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 24
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Unusual prolonged survival in multiple system atrophy: A case report
  • An atypical and interesting feature of Parkinson´s disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley